Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis

Inclusion Criteria: * Diagnosed with auto-immune hepatitis based on liver biopsy results, with the indications of immunosuppressive therapy; * High levels of total bilirubin (TB) (≥10 X ULN); * High levels of immunoglobulin G(IgG) (≥1.5 X ULN); * Agreed to participate in the trial, and assigned informed consent; Exclusion Criteria: * The presence of hepatitis A, B, C, D, or E virus infection; * Patients with presence of liver cirrhosis or portal hypertension; * Primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson disease confirmed by liver biopsy; * Pregnant and breeding women; * Patients with severe anemia (hemoglobin \< 8 g/dL), leukopenia (WBC \< 2500/mm3), or thrombocytopenia (platelet count \< 50,000/mm3); * Severe disorders of other vital organs, such as severe heart failure, cancer; * Parenteral administration of blood or blood products within 6 months before screening; * Recent treatment with drugs having known liver toxicity; * Taken part in other clinic trials within 6 months before screening.